Gut microbiome alterations in Alzheimer's diseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared the gut microbiome composition of 25 participants with dementia due to Alzheimer's disease to 25 age and sex matched cognitively healthy controls.
How was it studied?
Fecal samples underwent 16S rRNA gene sequencing to characterize bacterial taxa from phylum down to genus level. A subset of participants who had also undergone lumbar puncture allowed correlation of bacterial abundance with cerebrospinal fluid biomarkers of Alzheimer's pathology.
What did they find?
The Alzheimer's group showed decreased microbial richness and diversity and a distinct overall composition. Firmicutes and Bifidobacterium were decreased while Bacteroidetes was increased, and these genus-level shifts correlated with CSF amyloid and tau biomarkers.
Why it matters
This adds Alzheimer's disease to the list of conditions linked to gut microbial alterations. It suggests gut bacterial communities could be explored as a therapeutic target.